Solutions for gluten-related disorders

Targeted enzymatic digestion of gluten immunogenic peptides

AMYRA

Biotech AG

AMYRA Biotech AG

AMYRA Biotech AG is a private Swiss joint stock company based in Basel.

The multidisciplinary team brings together complementary expertise in drug development, biotechnology, immunology, medicine and business.

AMYRA collaborates intensively with universities, research institutes, industry partners and healthcare professionals.

AMYRA's mission is to deliver safe and effective therapeutics for the prevention of gluten-related health disorders.

Dr. Werner Tschollar, CEO & founder

AMYRA's mission is to deliver safe and effective therapeutics for the prevention of gluten-related health disorders.​​

Dr. Werner Tschollar, CEO & founder

A unique approach

AMYRA Products

Foundation

Scientific research has shown that partially digested gluten fragments, known as gluten immunogenic peptides (GIPs) trigger an autoimmune response in genetically predisposed people, namely celiac disease.

GIPs also play a role in the immune pathology of  non-celiac gluten sensitivity, a clinical syndrome distinct from celiac disease. 

AMYRA has developed a unique technology able to target GIPs in the intestine, where the pathology of celiac disease and non-celiac gluten sensitivity takes place.

AMYRA’s novel exopeptidase combinations have demonstrated
rapid and complete digestion of GIPs
down to physiologically harmless amino-acids.

development

Latest Updates